In older adults, an Ad26.RSV.preF-RSV preF protein vaccine reduced RSV-related lower respiratory tract disease

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

SOURCE CITATION: Falsey AR, Williams K, Gymnopoulou E, et al; CYPRESS Investigators. Efficacy and safety of an Ad26.RSV.preF-RSV preF protein vaccine in older adults. N Engl J Med. 2023;388:609-620. 36791161.

Original languageEnglish (US)
JournalAnnals of Internal Medicine
Volume176
Issue number6
Early online dateJun 6 2023
DOIs
StatePublished - Jun 2023

Keywords

  • Aged
  • Antibodies, Viral
  • Humans
  • Respiratory Syncytial Virus Infections/prevention & control
  • Respiratory Syncytial Virus Vaccines
  • Respiratory Tract Diseases

ASJC Scopus subject areas

  • Internal Medicine

Fingerprint

Dive into the research topics of 'In older adults, an Ad26.RSV.preF-RSV preF protein vaccine reduced RSV-related lower respiratory tract disease'. Together they form a unique fingerprint.

Cite this